GrayMatters Health develops neuroscience-based digital technologies designed to support accessible, evidence-based mental health care. Its Prism suite combines fMRI-informed digital biomarkers with computer simulations to help patients learn to regulate brain activity associated with their condition. The approach is intended to augment standard-of-care therapies and support personalized treatment in psychiatry clinics.

Prism includes protocols for post-traumatic stress disorder (PTSD) and depression. The PTSD protocol uses an amygdala-based biomarker, while the depression protocol uses a reward-system biomarker based on the ventral striatum. In sessions, patients explore personal memories, emotions, or experiences as mental strategies to influence the simulation and practice skills they can use in daily life. GrayMatters also presents Prism as operationally adaptable for clinics, requiring a quiet room, a table, a chair, and a trained operator. The company offers provider-finding resources and account-management support to help practices establish a Prism service. Its website also shares clinical research, case studies, and information about its biomarker technology, while advising patients to discuss care with a qualified mental health professional.